This is an important question and specific evidence is not still available. However, based on experience with influenza and pneumococcal vaccines, commonly administered to these patients , Rheumatology societies ( i.e ACR or EULAR) have released recommendations. Although cases must be considered individually by physicians and patients, vaccination is basically recommended for patients with autoimmune diseases in remission, even for those receiving immunosuppressive therapy including biologic agents. Vaccine is not recommended for those with active disease.
Based on the study of pneumococcal and influenza vaccination in immunocompromised patients, experts give opinion that Covid vaccine may be given in an immunocompromised patient
Administration of the vaccine in those taking immunosuppressants and having immune dysregulation has two aspects: Does the vaccine causes flare of the immune dysregulation? Does the vaccine produce a sufficient protective response? As the vaccine gets distributed, we will be able to answer these questions.
The technology used in mRNA vaccines/nanoparticles is novel as well. We can not draw parallels with previously approved vaccines. Although pneumococcal vaccine can cause disease flare and live-virus-based vaccines are not recommended for immune-suppressed patients, at this stage, there is no clear signal that the mRNA vaccines cause disease flare.
The type I hypersensitive reaction to the nanoparticles is known and reported in other mRNA vaccines, currently in early-stage trials for cancer and HIV. So what is for sure needs to be done is 10-15 min observation right after receiving the vaccine.